Bachem celebrated its fifty-year anniversary on June 16, 2021.
Bachem was founded in 1971 by the entrepreneur Peter Grogg. Over the course of half a century Bachem has become a global leader in the development and production of peptides, important ingredients for a range of vital medicines that treat cancer, diabetes and other diseases.
Somatostatin is a hormone that inhibits the release of other hormones. Somatostatin analogues like octreotide, lanreotide and pasireotide are synthetic versions of somatostatin optimized for an effective therapeutic use. They often require complex injectable formulations for a convenient long acting application and non-parenteral formulations that could significantly improve the treatment especially in juveniles are in development.
SOMATOSTATIN ANALOGUES PROVIDE INVALUABLE THERAPEUTIC OPTIONS
For decades, somatostatin-related drugs have been of interest in the areas of endocrinology and oncology. Somatostatin was initially viewed as an attractive candidate for the treatment of cancer due to its ability to block hormone release and cell growth after binding to its receptors; however, the native somatostatin peptide exhibited disadvantages such as a short half-life and rebound hypersecretion upon discontinuation. To overcome these obstacles, the design of somatostatin analogues with longer half-lives and improved pharmacologic efficacy have continued to be a focus of drug development.
MEET BACHEM: PASCAL HESS, GROUP LEADER GENERICS - PORTFOLIO
This month's spotlight is on Pascal Hess, Group Leader Generics - Portfolio in the Sales Generics Department at Bachem AG. Learn more about Pascal 's role at Bachem and what he likes to do in his free time.
This month's highlights include news about a double-blind placebo-controlled trial with oral octreotide therapy on 40 participants with acromegaly, about a case report on the successful control of cortisol fluctuations in a woman with Cushing’s disease with Signifor (pasireotide LAR), about re-engineering peptide design and about the development of short chunk of peptides that block viruses in childhood respiratory infections.
Learn about peptide generic APIs, small molecule APIs, and fields of applications in our generic APIs flyer.
WEBINAR ARCHIVE
Benefit from Bachem’s experts. Join our free webinars. Our upcoming webinars are listed our events calendar, but you can access recordings on our webinar archive page.
